{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T10:33:16Z","timestamp":1792492396870,"version":"4.5.0"},"reference-count":43,"publisher":"National Academy of Sciences","issue":"48","license":[{"start":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T00:00:00Z","timestamp":1668988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Intramural Research Program of the NIH","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2022,11,29]]},"abstract":"<jats:p>\n                    LMB-100 is a recombinant immunotoxin composed of a Fab linked to a toxin. It kills cells expressing human mesothelin (hMSLN), which is highly expressed on the surface of mesothelioma and many other cancer cells. Clinically, we observed some patients had delayed responses to an anti-hMSLN immunotoxin treatment, suggesting the induction of anti-tumor immunity. We aimed to develop a mouse model to investigate whether immunotoxin alone can induce anti-tumor immunity and to study the mechanism of this immunity. An immunocompetent transgenic mouse was used to grow mouse mesothelioma AB1 cells expressing hMSLN in the peritoneal cavity. Mice were treated with LMB-100, and mice with complete responses (CRs) were rechallenged with tumor cells to determine whether anti-tumor immunity developed. Changes in gene expression profiles were evaluated by Nanostring, and changes in cytokines and chemokines were checked by protein arrays. The distribution of various immune cells was assessed by immunohistochemistry. Our results show that the mice with tumor reached CRs and developed anti-tumor immunity after LMB-100 treatment alone. The primary response requires CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells, CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells, and B cells. Transcriptional profiling shows that LMB-100 treatment reshapes the tumor immune microenvironment by upregulating chemotaxis signals. LMB-100 treatment upregulates genes associated with tertiary lymphoid structures (TLS) development and induces TLS formation in tumors. In sum, immunotoxin-mediated cell death induces anti-tumor immunity and the development of TLS, which provides insights into how immunotoxins cause tumor regressions.\n                  <\/jats:p>","DOI":"10.1073\/pnas.2214928119","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T15:18:11Z","timestamp":1669043891000},"update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":21,"title":["Anti-mesothelin immunotoxin induces mesothelioma eradication, anti-tumor immunity, and the development of tertiary lymphoid structures"],"prefix":"10.1073","volume":"119","author":[{"given":"Wenlong","family":"Liu","sequence":"first","affiliation":[{"name":"Center for Cancer Research, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Hsien","family":"Tai","sequence":"additional","affiliation":[{"name":"Center for Cancer Research, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufen","family":"Liu","sequence":"additional","affiliation":[{"name":"Center for Cancer Research, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9223-0270","authenticated-orcid":false,"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[{"name":"Center for Cancer Research, Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4264"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2022,11,21]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67025-0"},{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32714-8"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.1.136"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200311000-00003"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.68.3672"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0337"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0583"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0210-1"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01261"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2016.07.003"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0358"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins11010020"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006941"},{"key":"e_1_3_4_14_2","doi-asserted-by":"crossref","unstructured":"Q. Jiang Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. Sci. Transl. Med. 12 eaaz7252 (2020). eaaz7252","DOI":"10.1126\/scitranslmed.aaz7252"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0330"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3390\/toxins10110470"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000263"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2018.08.016"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2010.12.018"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","unstructured":"R. M. Zemek Sensitization to immune checkpoint blockade through activation of a STAT1\/NK axis in the tumor microenvironment. Sci. Transl. Med. 11 eaav7816 (2019). eaav7816","DOI":"10.1126\/scitranslmed.aav7816"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.674375"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers6020969"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2592419"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1914-8"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0144-6"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0915000107"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701269"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5804230"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni1330"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0881-6"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.269"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1009285"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1922-8"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1906-8"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-1987"},{"key":"e_1_3_4_37_2","doi-asserted-by":"crossref","unstructured":"M. Chelvanambi STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. J. Immunother. Cancer 9 e001906 (2021). e001906","DOI":"10.1136\/jitc-2020-001906"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24347-7"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910520609"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1717063115"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2071-9"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-307983"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8"}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.2214928119","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T08:29:20Z","timestamp":1695284960000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/10.1073\/pnas.2214928119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,21]]},"references-count":43,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2022,11,29]]}},"alternative-id":["10.1073\/pnas.2214928119"],"URL":"https:\/\/doi.org\/10.1073\/pnas.2214928119","relation":{},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,21]]},"assertion":[{"value":"2022-09-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e2214928119"}}